Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Patient Assistance Program
Don’t let the high cost of brand subcutaneous HER2-targeted therapy disrupt your breast cancer treatment. We help eligible patients access Herceptin Hylecta (trastuzumab and hyaluronidase-oysk SC injection) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is FDA-approved for HER2-overexpressing breast cancer treatment — same trastuzumab as IV Herceptin, formulated with recombinant hyaluronidase for subcutaneous injection over 2–5 minutes (vs 30–90 minute IV infusion). Same clinical efficacy as IV Herceptin. Adjuvant and metastatic breast cancer indications.
- Without assistance, Herceptin Hylecta costs commonly run approximately $8,000–$10,000 per injection.
- Through AffordMyPrescriptions, qualifying patients can access Herceptin Hylecta for a flat $69.95 per month.
- Trastuzumab biosimilars now widely available and IV: Kanjinti, Ontruzant, Trazimera, Herzuma, Ogivri — all with efficacy equivalent to Herceptin at lower cost. Herceptin Hylecta is uniquely subcutaneous. Other HER2-targeted therapies: Perjeta (pertuzumab), Kadcyla (T-DM1 ADC), Enhertu (trastuzumab deruxtecan — more potent ADC), Phesgo (fixed-dose SC pertuzumab + trastuzumab + hyaluronidase), Nerlynx (neratinib oral), Tukysa (tucatinib oral). Comprehensive breast cancer molecular testing is critical.
What is Herceptin Hylecta Prescription Assistance Program?
The Herceptin Hylecta Patient Assistance Program helps eligible patients access this SC HER2-targeted therapy at little or no cost when meeting income, insurance, and clinical criteria. Free to apply but involves detailed applications, oncology coordination, HER2 status documentation, and renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Herceptin Hylecta PAP enrollment for a flat $69.95 per month — so you never face a gap in your Herceptin Hylecta breast cancer therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Herceptin Hylecta enrollment — so you never face a gap in your HER2-positive breast cancer treatment.
Pharmacy Price Comparison
- Without assistance, Herceptin Hylecta costs thousands per injection. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Phesgo (SC alt w/pertuzumab) | varies | Alt SC combo with pertuzumab |
| Cancer center pharmacy | ~$9,500/dose | Save substantially |
| Community oncology | ~$10,000/dose | Save substantially |
| Hospital outpatient | ~$9,000/dose | Save substantially |
| 340B-eligible institution | ~$8,000/dose | Save substantially |
| Trastuzumab biosimilar (IV) | ~$4,000/dose | IV biosimilar cheaper |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Herceptin Hylecta — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Herceptin Hylecta Prescription Program?
The Herceptin Hylecta Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Trastuzumab biosimilars (IV) provide significant cost savings if the SC formulation isn’t essential. Herceptin Hylecta’s 2–5 minute SC injection is an advantage vs a 30–90 minute IV infusion. HER2 status validation with IHC and/or FISH is required.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Herceptin Hylecta assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Herceptin Hylecta is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Herceptin Hylecta:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $8,000–$10,000/dose even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Herceptin Hylecta assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Herceptin Hylecta Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Herceptin Hylecta:
Herceptin Hylecta is a subcutaneous formulation of trastuzumab with recombinant hyaluronidase enabling injection administration over 2–5 minutes instead of IV infusion over 30–90 minutes. Same trastuzumab, same efficacy — with substantially reduced chair time and infusion suite burden for patients on maintenance HER2 therapy.
How It Works:
HER2 (human epidermal growth factor receptor 2)-positive breast cancer accounts for ~15–20% of all breast cancers — HER2 amplification/overexpression drives cell proliferation and portends poor prognosis without targeted therapy. HER2-targeted antibody therapy revolutionized outcomes. Trastuzumab binds the HER2 extracellular domain — inhibiting HER2 signaling, promoting internalization/degradation, and mediating antibody-dependent cellular cytotoxicity (ADCC). The hyaluronidase in Herceptin Hylecta transiently digests extracellular matrix hyaluronan, allowing large-volume subcutaneous injection with rapid absorption — equivalent PK/PD to IV administration. Trastuzumab biosimilars offer the same mechanism at lower cost via the IV route.
Form and Use:
Herceptin Hylecta SC injection. Fixed dose 600 mg (trastuzumab) + hyaluronidase every 3 weeks. Administered over 2–5 minutes in the thigh. Cardiac function monitoring (LVEF) at baseline and periodically during therapy. Cancer center or oncology clinic administration.
Generic Availability:
No generic Herceptin Hylecta. Trastuzumab biosimilars (all IV): Kanjinti, Ontruzant, Trazimera, Herzuma, Ogivri — biosimilars to Herceptin with equivalent efficacy at lower cost. Herceptin Hylecta uniquely offers an SC formulation. Phesgo (SC pertuzumab + trastuzumab + hyaluronidase fixed-dose combination) provides SC dual HER2 blockade. Other HER2-targeted therapies: Perjeta (pertuzumab), Kadcyla (T-DM1 ADC), Enhertu (T-DXd — more potent ADC now first-line for metastatic HER2+), Nerlynx (neratinib oral), Tukysa (tucatinib oral). Susan G. Komen and other advocacy resources.
Warnings:
Cardiotoxicity (heart failure — monitor LVEF), pulmonary toxicity (pulmonary events including infusion reactions and interstitial lung disease), embryo-fetal toxicity (contraindicated in pregnancy — HER2 is essential for fetal development), infusion reactions (less common than IV but still possible), and local injection site reactions (SC formulation). Boxed warnings for cardiotoxicity and embryo-fetal toxicity. Other: fatigue, headache, upper respiratory infections, nausea. Cardiology and oncology coordination for LVEF monitoring. Pregnancy considerations essential.
FAQ (Frequently Asked Questions)
How much does Herceptin Hylecta cost without insurance?
$8,000–$10,000 per SC injection at cancer centers. With 3-week dosing, monthly cost is $12,000–$14,000. IV trastuzumab biosimilars are significantly cheaper (~$4,000/dose IV) — if the SC administration convenience isn’t essential.
How is Herceptin Hylecta different from IV Herceptin?
Same trastuzumab molecule. The SC formulation with recombinant hyaluronidase enables injection over 2–5 minutes instead of IV infusion over 30–90 minutes — same efficacy and safety. Major advantage: dramatically reduced chair time for patients on prolonged HER2 therapy (adjuvant is 1 year; metastatic often indefinite).
How does Herceptin Hylecta compare to trastuzumab biosimilars?
Trastuzumab biosimilars (Kanjinti, Ontruzant, Trazimera, Herzuma, Ogivri) are IV formulations biosimilar to Herceptin — significantly cheaper. Herceptin Hylecta’s advantage is SC administration convenience. Choose based on cost, convenience preference, and insurance coverage. Same clinical efficacy for HER2+ breast cancer.
What is HER2-positive breast cancer?
Breast cancer with HER2 protein overexpression or gene amplification — ~15–20% of breast cancers. Confirmed by immunohistochemistry (IHC 3+) and/or fluorescence in situ hybridization (FISH). HER2-targeted therapy revolutionized outcomes for this subtype — historically among the worst-prognosis breast cancers, now very treatable.
What are Herceptin Hylecta side effects?
Generally well-tolerated. Cardiotoxicity risk (monitor LVEF), infusion/injection reactions (less common with SC than IV), fatigue, headache, upper respiratory infections, nausea, injection site reactions. Cardiology monitoring is important given the risk of asymptomatic LVEF decline.
Take Control of Your Medication Costs
HER2-targeted therapy transformed HER2-positive breast cancer outcomes — subcutaneous convenience is a meaningful patient benefit. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.